|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases response to substance |
ISO |
GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Ethacrynic Acid] |
CTD |
PMID:10900222 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport |
ISO |
ABCC2 protein results in increased transport of Ethacrynic Acid |
CTD |
PMID:16316932 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of AKR1C1 mRNA |
CTD |
PMID:9973208 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [4-nitrobenzaldehyde affects the reduction of AKR7A5 protein] |
CTD |
PMID:12604212 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression multiple interactions |
ISO |
Ethacrynic Acid results in increased expression of BCL2L1 protein [arsenic trioxide co-treated with Ethacrynic Acid] results in increased expression of BCL2L1 protein |
CTD |
PMID:23082001 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in decreased expression of BIRC5 protein |
CTD |
PMID:23082001 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein; [MCL1 mutant form results in increased susceptibility to [Ethacrynic Acid co-treated with arsenic trioxide]] which results in increased cleavage of CASP3 protein; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein] |
CTD |
PMID:23082001 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP8 protein Ethacrynic Acid results in increased cleavage of CASP8 protein |
CTD |
PMID:23082001 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO |
Ethacrynic Acid results in increased cleavage of CASP9 protein arsenic trioxide promotes the reaction [Ethacrynic Acid results in increased cleavage of CASP9 protein]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein]; MCL1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein] |
CTD |
PMID:23082001 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT mutant form promotes the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]] |
CTD |
PMID:23082001 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Ethacrynic Acid results in decreased expression of CCND1 mRNA |
CTD |
PMID:20011538 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of CDKN1A mRNA |
CTD |
PMID:25817893 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of CFLAR protein] |
CTD |
PMID:23082001 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Ethacrynic Acid results in increased expression of CYP1A1 mRNA Ethacrynic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:9973208 PMID:18493746 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Ethacrynic Acid results in increased expression of DDIT3 mRNA]; Glutathione inhibits the reaction [Ethacrynic Acid results in increased expression of DDIT3 mRNA] |
CTD |
PMID:17171638 PMID:25817893 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
Ethacrynic Acid results in decreased expression of FN1 mRNA |
CTD |
PMID:20011538 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of FOS mRNA |
CTD |
PMID:10407097 PMID:12946577 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fzd5 |
frizzled class receptor 5 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of FZD5 mRNA |
CTD |
PMID:20011538 |
|
NCBI chr 9:66,117,370...66,119,127
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Ethacrynic Acid |
CTD |
PMID:10900222 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Ethacrynic Acid |
CTD |
PMID:10900222 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
decreases response to substance increases expression multiple interactions affects metabolic processing |
ISO EXP |
GSTA1 protein results in decreased susceptibility to Ethacrynic Acid Ethacrynic Acid results in increased expression of GSTA1 mRNA [GSTA1 protein binds to GSTA2 protein] which affects the metabolism of Ethacrynic Acid GSTA1 protein affects the metabolism of Ethacrynic Acid analog |
CTD |
PMID:1985777 PMID:9799558 PMID:9877184 PMID:12781783 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
affects metabolic processing multiple interactions |
EXP |
GSTA2 protein affects the metabolism of Ethacrynic Acid [GSTA1 protein binds to GSTA2 protein] which affects the metabolism of Ethacrynic Acid |
CTD |
PMID:9877184 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases glutathionylation |
ISO |
GSTA3 protein results in increased glutathionylation of Ethacrynic Acid |
CTD |
PMID:21876218 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression affects metabolic processing |
EXP |
Ethacrynic Acid results in increased expression of GSTA4 mRNA; Ethacrynic Acid results in increased expression of GSTA4 protein GSTA4 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:2619714 PMID:9799558 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects metabolic processing |
ISO |
GSTM1 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:12069689 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm7 |
glutathione S-transferase, mu 7 |
affects metabolic processing |
ISO |
GSTM7 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:12069689 |
|
NCBI chr 2:195,566,701...195,572,149
Ensembl chr 2:195,566,701...195,572,203
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases activity affects metabolic processing decreases response to substance increases expression multiple interactions |
ISO EXP |
Ethacrynic Acid analog results in decreased activity of GSTP1 protein; Ethacrynic Acid results in decreased activity of GSTP1 protein GSTP1 protein affects the metabolism of Ethacrynic Acid GSTP1 protein results in decreased susceptibility to Ethacrynic Acid GSTP1 protein affects the metabolism of Ethacrynic Acid analog Ethacrynic Acid results in increased expression of GSTP1 protein Ethacrynic Acid binds to and results in decreased activity of GSTP1 protein; Ethacrynic Acid inhibits the reaction [Chlorophyllides inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]]; Ethacrynic Acid inhibits the reaction [GSTP1 protein affects the metabolism of Isotretinoin]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Ethacrynic Acid]; GSTP1 protein results in decreased susceptibility to [arsenic trioxide co-treated with Ethacrynic Acid]; Pyrimethamine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid]; Quinidine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid]; Quinine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid]; Tetracycline inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid] |
CTD |
PMID:2619714 PMID:2747627 PMID:9463521 PMID:9806904 PMID:9877184 PMID:10900222 PMID:11807801 PMID:12781783 PMID:14556662 PMID:15911318 PMID:15999103 PMID:23082001 PMID:23769903 More...
|
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
affects metabolic processing |
EXP |
GSTT2 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:2114406 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
affects metabolic processing |
ISO |
GSTZ1 protein affects the metabolism of Ethacrynic Acid |
CTD |
PMID:9396740 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Acetylcysteine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of HMOX1 protein]; Deferoxamine inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Glutathione inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 mRNA]; Glutathione inhibits the reaction [Ethacrynic Acid results in increased expression of HMOX1 protein] Ethacrynic Acid results in increased expression of HMOX1 mRNA; Ethacrynic Acid results in increased expression of HMOX1 protein |
CTD |
PMID:20934533 PMID:25817893 PMID:26945724 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Ethacrynic Acid results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Ethacrynic Acid co-treated with arsenic trioxide] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [[Ethacrynic Acid co-treated with arsenic trioxide] results in increased phosphorylation of JUN protein] |
CTD |
PMID:23082001 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression affects binding |
ISO |
Ethacrynic Acid results in decreased expression of LEF1 mRNA Ethacrynic Acid binds to LEF1 protein |
CTD |
PMID:20011538 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
LOC102556347 |
carbonyl reductase [NADPH] 1-like |
multiple interactions |
ISO |
Ethacrynic Acid inhibits the reaction [CBR1 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] |
CTD |
PMID:11306090 |
|
NCBI chr11:32,892,640...32,895,277
Ensembl chr11:32,857,991...32,895,275
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of MAP2K1 protein |
CTD |
PMID:14556662 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
ISO |
Ethacrynic Acid results in decreased expression of MAPK14 protein |
CTD |
PMID:14556662 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of MAPK3 protein |
CTD |
PMID:14556662 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
decreases expression |
ISO |
Ethacrynic Acid results in decreased expression of MAPK8 protein |
CTD |
PMID:14556662 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression |
ISO |
[MCL1 mutant form results in increased susceptibility to [Ethacrynic Acid co-treated with arsenic trioxide]] which results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; CAT mutant form promotes the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; MCL1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein]; MCL1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; MCL1 mutant form results in increased susceptibility to [Ethacrynic Acid co-treated with arsenic trioxide]; pyrazolanthrone inhibits the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]] |
CTD |
PMID:23082001 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization affects response to substance increases expression |
ISO |
NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Ethacrynic Acid] ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]] [NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Ethacrynic Acid Ethacrynic Acid results in increased expression of NFE2L2 protein |
CTD |
PMID:19303893 PMID:20932822 PMID:20934533 PMID:25817893 PMID:26945724 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
increases expression |
ISO |
Ethacrynic Acid results in increased expression of NGF mRNA |
CTD |
PMID:10407097 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Ethacrynic Acid promotes the reaction [Potassium Cyanide results in increased expression of NOS2 protein] |
CTD |
PMID:16933320 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; GSTP1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; MCL1 mutant form promotes the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[arsenic trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein] |
CTD |
PMID:23082001 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
decreases activity multiple interactions |
ISO |
Ethacrynic Acid results in decreased activity of SLC12A2 protein Ethacrynic Acid inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium] |
CTD |
PMID:29959396 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Tp53 |
tumor protein p53 |
affects localization |
ISO |
Ethacrynic Acid affects the localization of TP53 protein |
CTD |
PMID:25817893 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ethacrynic Acid] results in decreased expression of XIAP protein |
CTD |
PMID:23082001 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|